Janus Henderson Group PLC Purchases 532,284 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Janus Henderson Group PLC boosted its position in Structure Therapeutics Inc. (NASDAQ:GPCR) by 34.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,076,700 shares of the company’s stock after acquiring an additional 532,284 shares during the period. Janus Henderson Group PLC’s holdings in Structure Therapeutics were worth $88,994,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Boxer Capital LLC bought a new position in shares of Structure Therapeutics in the 4th quarter valued at about $16,304,000. Federated Hermes Inc. grew its stake in shares of Structure Therapeutics by 104.2% during the fourth quarter. Federated Hermes Inc. now owns 2,267,206 shares of the company’s stock worth $92,411,000 after purchasing an additional 1,157,006 shares during the period. Avoro Capital Advisors LLC lifted its stake in Structure Therapeutics by 133.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company’s stock valued at $95,107,000 after buying an additional 1,333,333 shares during the period. Octagon Capital Advisors LP bought a new position in Structure Therapeutics during the fourth quarter worth about $16,875,000. Finally, Bellevue Group AG boosted its stake in Structure Therapeutics by 2,858.7% during the 1st quarter. Bellevue Group AG now owns 363,926 shares of the company’s stock worth $15,598,000 after acquiring an additional 351,626 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Down 0.7 %

Shares of NASDAQ GPCR traded down $0.25 during trading hours on Wednesday, hitting $35.84. The company had a trading volume of 154,197 shares, compared to its average volume of 826,993. Structure Therapeutics Inc. has a 1-year low of $25.57 and a 1-year high of $75.02. The firm’s 50 day moving average is $42.27 and its 200-day moving average is $41.16. The stock has a market capitalization of $1.67 billion, a P/E ratio of -46.87 and a beta of -3.58.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. On average, sell-side analysts predict that Structure Therapeutics Inc. will post -0.94 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on GPCR. BMO Capital Markets raised their price objective on Structure Therapeutics from $83.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, June 7th. JMP Securities reissued a “market outperform” rating and set a $91.00 target price on shares of Structure Therapeutics in a research note on Friday, May 10th. JPMorgan Chase & Co. began coverage on shares of Structure Therapeutics in a research note on Tuesday, May 21st. They issued an “overweight” rating and a $65.00 price target on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, July 1st. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $85.25.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.